Lancet https://doi.org/10.1016/S0140-6736(20)31605-6 & https://doi.org/10.1016/S0140-6736(20)31604-4 (2020); N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2022483 (2020)
Two approaches for vaccines against COVID-19 are safe, suggest the induction of relevant immune responses and will be pursued further.
The COVID-19 pandemic has necessitated the rapid development of a vaccine against the causative coronavirus SARS-CoV-2 and has resulted in the acceleration of new technologies.
One approach to the vaccine is to inoculate people with viral vectors that express the spike protein of SARS-CoV-2, and another is to use an mRNA encoding the spike protein. A group in China using an adenovirus-vectored vaccine reports the results of a phase 2 trial of 508 people, and a group in Oxford reports a phase 1/2 trial of a chimpanzee adenovirus-vectored vaccine in 1,077 people. A phase 1 trial of an mRNA-based approach in 45 people has been also been reported. All trials indicate good safety and potential to take the vaccine to the next stage.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Stower, H. Seeds of hope in COVID-19 vaccine preliminary data. Nat Med 26, 1170 (2020). https://doi.org/10.1038/s41591-020-1031-0
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-020-1031-0